Incidence of Immediate Gadolinium Contrast Media Reactions

Prince, Martin R.; Zhang, Honglei; Zou, Zhitong; Staron, Ronald B.; Brill, Paula W.

doi:10.2214/ajr.10.4885

Cited by 246 publications

(178 citation statements)

References 22 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…Our results are completely in line with the recently published data extracted from the Euro-CMR study in which 30 acute adverse reactions (0.17%) occurred in a large cohort of 17,767 doses administered [31]. Similar findings were reported in larger studies analyzing the incidence of gadolinium-related contrast media reactions reporting event rates ranging between 0.04 and 2.2% [32][33][34].…”

Section: Safety Profilesupporting

confidence: 92%

“…We could not analyze differences in reaction rates between the various gadolinium-based contrast molecules due to the limited number of events observed in our population although a lower adverse reactions incidence for nonionic gadolinium-based contrast agents has been reported in literature as compared to ionic linear or macrocyclic agents [32].…”

Section: Safety Profilementioning

confidence: 94%

See 1 more Smart Citation

Italian registry of cardiac magnetic resonance

Francone¹,

Cesare²,

Cademartiri³

et al. 2014

European Journal of Radiology

View full text Add to dashboard Cite

Objectives Forty sites were involved in this multicenter and multivendor registry, which sought to evaluate indications, spectrum of protocols, impact on clinical decision making and safety profile of cardiac magnetic resonance (CMR). Materials and methods Data were prospectively collected on a 6-month period and included 3376 patients (47.2 ± 19 years; range 1-92 years). Recruited centers were asked to complete a preliminary general report followed by a single form/patient. Referral physicians were not required to exhibit any specific certificate of competency in CMR imaging. Results Exams were performed with 1.5 T scanners in 96% of cases followed by 3 T (3%) and 1 T (1%) magnets and contrast was administered in 84% of cases. The majority of cases were performed for the workup of inflammatory heart disease/cardiomyopathies representing overall 55.7% of exams followed by the assessment of myocardial viability and acute infarction (respectively 6.9% and 5.9% of patients). In 49% of cases the final diagnosis provided was considered relevant and with impact on patient's clinical/therapeutic management. Safety evaluation revealed 30 (0.88%) clinical events, most of which due to patient's preexisting conditions. Radiological reporting was recorded in 73% of exams. Conclusions CMR is performed in a large number of centers in Italy with relevant impact on clinical decision making and high safety profile. © 2013 Elsevier Ireland Ltd

show abstract

Section: Safety Profilesupporting

confidence: 92%

Section: Safety Profilementioning

confidence: 94%

Italian registry of cardiac magnetic resonance

Francone¹,

Cesare²,

Cademartiri³

et al. 2014

European Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…Administration of GBCA is associated with a small risk of anaphylaxis44 and development of nephrogenic systemic fibrosis (NSF). The latter has been associated especially with linear GBCA and renal dysfunction 45.…”

Section: Resultsmentioning

confidence: 99%

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

et al. 2016

View full text Add to dashboard Cite

Multiple sclerosis (MS) is associated with inflammatory lesions in the brain and spinal cord. The detection of such inflammatory lesions using magnetic resonance imaging (MRI) is important in the consideration of the diagnosis and differential diagnoses of MS, as well as in the monitoring of disease activity and predicting treatment efficacy. Although there is strong evidence supporting the use of MRI for both the diagnosis and monitoring of disease activity, there is a lack of evidence regarding which MRI protocols to use, the frequency of examinations, and in what clinical situations to consider MRI examination. A national workshop to discuss these issues was held in Stockholm, Sweden, in August 2015, which resulted in a Swedish consensus statement regarding the use of MRI in the care of individuals with MS. The aim of this consensus statement is to provide practical advice for the use of MRI in this setting. The recommendations are based on a review of relevant literature and the clinical experience of workshop attendees. It is our hope that these recommendations will benefit individuals with MS and guide healthcare professionals responsible for their care.

show abstract

“…Severe life-threatening anaphylactic and fatal reactions do occur, but are exceedingly rare (0.001% to 0.01%) [13,[15][16][17], with only 40 deaths reported in 51 million GBCA doses administered between 2004 and 2009 [18]. The rarity of severe reactions makes it difficult to analyze accurately any differences between the reactions associated with individual GBCAs.…”

Section: Acute Adverse Eventsmentioning

confidence: 99%

“…Jung et al [14] also identified female gender and the number of exposures to MR contrast media as risk factors. Previous allergic reaction to a GBCA [14,18] is also a risk factor. The recurrence rate of hypersensitivity-like reactions is nearly 30% [14].…”

Section: Acute Adverse Eventsmentioning

confidence: 99%

Gadolinium toxicity and treatment

Ramalho

Jay

et al. 2016

Magnetic Resonance Imaging

102

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oGadolinium based contrast agents (GBCAs) play an important role in the diagnostic evaluation of many patients. The safety of these agents has been once again questioned after gadolinium deposits were observed and measured in brain and bone of patients with normal renal function. This retention of gadolinium in the human body has been termed "gadolinium storage condition". The long-term and cumulative effects of retained gadolinium in the brain and elsewhere are not as yet understood. Recently, patients who report that they suffer from chronic symptoms secondary to gadolinium exposure and retention created gadolinium-toxicity on-line support groups. Their self-reported symptoms have recently been published. Bone and joint complaints, and skin changes were two of the most common complaints. This condition has been termed "gadolinium deposition disease". In this review we will address gadolinium toxicity disorders, from acute adverse reactions to GBCAs to gadolinium deposition disease, with special emphasis on the latter, as it is the most recently described and least known.

show abstract

Incidence of Immediate Gadolinium Contrast Media Reactions

Cited by 246 publications

References 22 publications

Italian registry of cardiac magnetic resonance

Italian registry of cardiac magnetic resonance

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Gadolinium toxicity and treatment

Contact Info

Product

Resources

About